AstraZeneca and MSD present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
Results showed an absolute difference of an additional 7.4 months in median overall survival for Lynparza plus abiraterone in this setting vs. abiraterone alone.Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone demonstrated median overall survival (OS) of 42.1 months versus 34.7 months for abiraterone plus placebo. This result represents a 7.4-month absolute difference in